Abstract Number: PP05 • ACR Convergence 2025
Mastering a Rare, Autoimmune Disease: My Journey Regaining Agency Through Education, Collaboration, and Community
Background/Purpose: After a complex diagnostic journey, my PCP working on a rheumatological theory ordered a myositis-specific autoantibody (MSA) panel. It revealed the presence of an…Abstract Number: 2065 • ACR Convergence 2025
Pain in Idiopathic Inflammatory Myopathies: A Global Study of Patient Experience
Background/Purpose: Pain remains a significant yet understudied aspect of idiopathic inflammatory myopathies (IIMs), considerably reducing quality of life despite advancements in immunomodulatory therapies. Information obtained…Abstract Number: 1218 • ACR Convergence 2025
Social Determinants Shape Health Outcomes in Idiopathic Inflammatory Myopathies: Insights from Lived Experience of 1,252 Patients
Background/Purpose: The impact of social determinants of health (SDoH)—including socioeconomic status, social support, and geographic context—on disease outcomes in idiopathic inflammatory myopathies (IIM) remains underexplored.…Abstract Number: 1197 • ACR Convergence 2025
Genetic Profiling of Idiopathic Inflammatory Myopathies in Indian Patients Reveals Genotype-Phenotype Correlation
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune muscle disorders with complex genetic underpinnings. Most genetic studies have focused on limited populations. This study explores…Abstract Number: 0344 • ACR Convergence 2025
Inpatient Zoledronic Acid for Glucocorticoid-Induced Osteoporosis Prevention
Background/Purpose: Glucocorticoids are widely used in rheumatology and are associated with increased fracture risk. The 2022 ACR Guideline for the Prevention and Treatment of Glucocorticoid-induced…Abstract Number: 0284 • ACR Convergence 2025
Glucocorticoid Tapering and Relapse Risk in Anti-ARS Antibody-Positive Myositis: A Retrospective Study in a Single-Center Cohort Treated with Immunosuppressants
Background/Purpose: Anti–synthetase syndrome is generally responsive to glucocorticoid (GC) therapy, though relapse frequently complicates tapering. Prolonged GC use is associated with adverse events and decreased…Abstract Number: PP01 • ACR Convergence 2025
When You Become the Story: A Journalist’s Approach to Managing Complex Care
Background/Purpose: As a journalist, I’ve spent my career digging for answers. But when I became the story, I had to learn how to ask the…Abstract Number: 2064 • ACR Convergence 2025
Kinematics Underlying IBM-induced Dysphagia
Background/Purpose: Dysphagia remains a key contributor to mortality in IBM due to its connection with aspiration pneumonia and malnutrition (Shelly et al., 2021). Compared to…Abstract Number: 1217 • ACR Convergence 2025
Validation and clincial use of anti-MDA5 test – LIA versus ELISA
Background/Purpose: Although immunoprecipitation (IP) remains the gold standard for detecting myositis autoantibodies, it is technically demanding and not widely available. Line immunoassay (LIA) has become…Abstract Number: 1196 • ACR Convergence 2025
Prevalence of and Factors Associated with Chronic Opioid Use among Individuals with Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) can be associated with significant pain and functional impairment. While the use of opioids has been documented in other inflammatory…Abstract Number: 0305 • ACR Convergence 2025
From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy
Background/Purpose: Inclusion body myositis (IBM) is a progressive and severe inflammatory muscle disease that primarily affects adults over 50 years of age. It presents with…Abstract Number: 0283 • ACR Convergence 2025
The Performance of Rule-Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records
Background/Purpose: Idiopathic inflammatory myopathies (IIM; including dermatomyositis, polymyositis, and inclusion body myositis) are heterogenous systemic inflammatory conditions that cause significant disability and morbidity. The study…Abstract Number: 2673 • ACR Convergence 2025
Quantitative 18F-FDG PET/CT analysis reveals new patterns of muscle involvement and prognostic indicators in idiopathic inflammatory myopathies: beyond proximal muscle weakness
Background/Purpose: To characterize muscle involvement in idiopathic inflammatory myopathies (IIMs) using detailed anatomical segmentation and volumetric 18F-FDG PET/CT analysis, and to evaluate the prognostic value…Abstract Number: 2063 • ACR Convergence 2025
Linking PROMIS scores to disease severity and treatment in dermatomyositis: a patient-centered evaluation
Background/Purpose: Dermatomyositis (DM) is a chronic inflammatory myopathy characterized by muscle weakness and skin rashes, yet its full impact on patient-reported outcomes remains under-explored. We…Abstract Number: 1215 • ACR Convergence 2025
Remission Rates and Predictors in Idiopathic Inflammatory Myopathy Subtypes: Insights from a Single-Center Cohort
Background/Purpose: With therapeutic advances in idiopathic inflammatory myopathy (IIM), achieving remission has become an important goal. However, comprehensive data on remission, particularly across IIM subtypes,…
- 1
- 2
- 3
- …
- 34
- Next Page »
